MaxCyte, Inc. MXCT
- Market cap
- $122.8M
- P/E
- 0.0×
Follow MXCT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 1.63 | 1.63 | 5.85 | 3.36 | 2.45 | 3.17 | 1.26 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 1.63 | 6.13 | 17.44 | 10.88 | 6.02 | 5.55 | 5.20 |
High Price
|
|||
| — | — | — | — | 65 | 84 | 125 | 143 | 114 | 91 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 11 | 19 | 21 | 22 | 26 | 34 | 44 | 41 | 39 | 33 |
Revenue
|
|||
| 89.34% | 89.61% | 88.96% | 88.44% | 89.43% | 89.24% | 88.48% | 88.51% | 81.62% | 81.16% |
Gross Margin
|
|||
| (3) | (13) | (11) | (13) | (12) | (19) | (24) | (38) | (41) | (45) |
EBT
|
|||
| (27.27%) | (70.91%) | (53.21%) | (59.64%) | (45.15%) | (56.30%) | (53.25%) | (91.85%) | (106.29%) | (135.14%) |
EBT Margin
|
|||
| (3) | 0 | (11) | (13) | (12) | (19) | (24) | (38) | (41) | (45) |
Net Income
|
|||
| 0 | 0 | 0 | 1 | 1 | 1 | 0 | (3) | (2) | 5 |
Depreciation
|
|||
| 0.34 | 0.39 | 0.42 | 0.38 | 0.38 | 0.37 | 0.44 | 0.40 | 0.37 | 0.31 |
Revenue/Sh
|
|||
| (0.11) | (0.27) | (0.22) | (0.23) | (0.17) | (0.21) | (0.23) | (0.37) | (0.39) | (0.42) |
Earnings/Sh
|
|||
| (0.06) | (0.27) | (0.26) | (0.16) | (0.13) | (0.12) | (0.15) | (0.21) | (0.26) | (0.32) |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | (0.02) | (0.03) | (2.96) | (2.86) | (0.04) | (0.02) | (0.02) |
Capex/Sh
|
|||
| (0.06) | (0.27) | (0.26) | (0.18) | (0.16) | (3.08) | (3.01) | (0.25) | (0.28) | (0.34) |
Free CF/Sh
|
|||
| 0.15 | 0.54 | 0.31 | 0.24 | 0.48 | 2.90 | 2.50 | 2.25 | 1.97 | 1.61 |
Book Value/Sh
|
|||
| 34 | 49 | 51 | 56 | 69 | 91 | 102 | 103 | 105 | 106 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 16.27 | 27.24 | 11.76 | 12.51 | 11.29 | 5.00 |
PS Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 12.82 | 3.51 | 2.05 | 2.22 | 2.11 | 0.96 |
PB Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 15.13 | 19.92 | 7.06 | 8.88 | 7.78 | 2.44 |
EV/Sales
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | (36.48) | (2.42) | (1.02) | (14.45) | (10.27) | (2.23) |
EV/FCF
|
|||
| (2) | (13) | (13) | (9) | (9) | (11) | (15) | (22) | (28) | (34) |
Op' Cash Flow
|
|||
| 0 | (1) | (1) | (1) | (2) | (269) | (291) | (4) | (2) | (2) |
Capex
|
|||
| (2) | (13) | (13) | (10) | (11) | (279) | (306) | (25) | (29) | (36) |
FCF
|
|||
| 10 | 31 | 20 | 15 | 34 | 255 | 237 | 172 | 156 | 104 |
Working Cap'
|
|||
| 5 | 7 | 6 | 5 | 5 | 7 | 19 | — | — | — |
Total Debt
|
|||
| (7) | (27) | (12) | (12) | (30) | (248) | (208) | (168) | (154) | (103) |
Net Debt
|
|||
| 5 | 26 | 16 | 14 | 33 | 263 | 254 | 232 | 206 | 171 |
Sh' Equity
|
|||
| (14.86%) | (166.91%) | (73.09%) | (42.21%) | (28.90%) | (11.36%) | (8.26%) | (13.67%) | (16.17%) | (20.20%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | (434.02%) | (204.47%) | (76.71%) | (37.31%) | (47.26%) | (61.81%) | (47.39%) |
ROIC
|
|||
| (28.58%) | (84.92%) | (53.85%) | (87.88%) | (50.47%) | (12.89%) | (9.12%) | (15.60%) | (18.73%) | (23.63%) |
ROE
|
|||
MaxCyte, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| APYX Apyx Medical Corporation | $119.2M | 0.0× | Compare |
| INGN Inogen, Inc | $138.8M | 0.0× | Compare |
| ECOR electroCore, Inc. | $102.3M | 0.0× | Compare |
| OWLT Owlet, Inc. | $148.2M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| QTRX Quanterix Corporation | $150.4M | 0.0× | Compare |
| ZOMDF Zomedica Corp. | $95.4M | 0.0× | Compare |
| LUCD Lucid Diagnostics Inc. | $170.3M | 0.0× | Compare |
| QSI Quantum-Si Incorporated | $172.9M | 0.0× | Compare |
MaxCyte, Inc. (MXCT) key facts
- MaxCyte, Inc. (MXCT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was GBP 33.0 million, down 14.5% from fiscal 2024.
- MaxCyte, Inc. reported a net loss of GBP 44.6 million, or a loss of GBP 0.42 per share, for fiscal 2025.
- As of September 25, 2026, MXCT traded at $1.17, a market capitalization of $122.8 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.0× sales.
- Return on equity was −23.6% and debt-to-equity 0.00.
MaxCyte, Inc. (MXCT) Latest News
23 Sep
MaxCyte, Inc. named Sidharth Kapileshwar Chief Corporate Development Officer. The Rockville, Md.-based cell-engineering company said Kapileshwar, most recently Danaher's Vice President of Innovation for the Life Sciences Platform, will lead corporate development, strategy and M&A to drive growth. Over nearly 25 years, he has held roles in corporate development, strategy, innovation and M&A at GE Healthcare, Beckman Coulter and Halma plc. He holds an MS in Engineering from Ohio State, an MBA from the University of Chicago Booth School of Business, and a BTech from IIT Bombay. CEO Maher Masoud praised his track record translating strategy into growth, and Kapileshwar said he intends to bring that momentum to MaxCyte. MaxCyte's Flow Electroporation technology and SeQure DX gene editing risk assessment services enable scalable cell engineering for diverse cell types and payloads, advancing development of cell therapies. Signals a strategic focus on growth through corporate development and potential M&A, with uncertain near-term impact.
19 Aug
MaxCyte launches CHANGE-seq-BE and ONE-seq-BE tools to enhance off-target assessment for genome editing therapies. New product launches strengthen MaxCyte position in genome editing therapy development.
MaxCyte Inc. conducted its Q2 2026 earnings call, covering financial results, operational updates, and forward guidance for the cell engineering company. Earnings call supplies key quarterly metrics and outlook that can shift near-term stock sentiment without altering long-term strategy.
13 Aug
MaxCyte Inc (MXCT) Q2 2026 earnings call highlighted a strategic pivot to enterprise focus as core growth driver. Strategic pivot to enterprise signals major shift that can significantly alter company trajectory and investor outlook.
12 Aug
MaxCyte, Inc. released its Q2 2026 earnings call summary covering financial results and outlook. Q2 earnings call details directly inform investors on revenue, guidance and strategic plans that shift valuation and sentiment.
MaxCyte reported Q2 results in its earnings call, covering revenue, operational updates, and forward guidance for its cell engineering platform. Q2 earnings and guidance updates typically produce moderate stock moves without altering long-term trajectory.
MaxCyte, Inc. (MXCT) released its financial results for the second quarter of 2026. Quarterly financial results shape near-term investor views on company performance without altering long-term strategy.
21 Jul
MaxCyte announces multi-platform technology license partnership with Genentech to advance cell therapy development. License partnership with Genentech expands MaxCyte technology use in cell therapy and strengthens commercial traction.
23 Jun
VectorBuilder partners with MaxCyte to advance clinical-grade cell engineering. Partnership expands MaxCyte clinical cell engineering reach without immediate major financial effects.
13 May
MaxCyte Inc (MXCT) Q1 2026 earnings call highlights revenue meeting expectations amid core business challenges. Revenue meeting expectations offers moderate financial stability without major strategic shifts.
12 May
MaxCyte, Inc. released Q1 2026 earnings call summary highlighting financial results, pipeline progress, and strategic updates for the cell engineering company. Quarterly earnings call summary details financial performance and pipeline advancements that could significantly sway investor sentiment and stock trajectory.
MaxCyte reported Q1 revenue growth, narrowed net loss, advanced clinical pipeline including CAR-T and CRISPR programs, strengthened partnerships with Janssen and others, and reaffirmed 2024 guidance amid robust cash position. Q1 earnings show financial improvement and pipeline progress with moderate influence on stock performance and investor sentiment.
MaxCyte, Inc. (MXCT) reported a Q1 net loss but surpassed analyst revenue estimates. Exceeding revenue estimates despite a Q1 loss moderately influences financial performance and investor sentiment.
MaxCyte, Inc. (MXCT) reported first quarter 2026 financial results and reiterated full-year 2026 guidance. Quarterly financial results and reiterated guidance offer moderate insight into performance stability without major strategic shifts.
25 Mar
MaxCyte, Inc. (MXCT) Q4 2025 earnings call summary covers financial results, operational updates, strategic partnerships, and forward-looking guidance for the cell engineering company. Q4 earnings summary details financial performance and partnerships that could significantly boost MXCT's market position and investor confidence.
24 Mar
MaxCyte (MXCT) Q4 2025 earnings call transcript details fourth-quarter financial results, operational updates, and forward-looking guidance. Q4 earnings call transcript discloses key financial metrics, strategic initiatives, and outlook likely to influence investor sentiment and stock trajectory.
MaxCyte's Q4 earnings call highlighted financial results, pipeline advancements in cell and gene therapies, strategic partnerships, and optimistic 2024 guidance. Q4 earnings highlights detail financial performance and pipeline progress likely to significantly influence MXCT's market performance and investor sentiment.
MaxCyte, Inc. (MXCT) reported fourth quarter and full year 2025 financial results and provided full year 2026 guidance. Earnings results and forward guidance directly shape investor expectations and stock valuation.
MaxCyte Inc (MXCT) Q4 2025 earnings call reveals revenue declines navigated through strategic initiatives amid ongoing developments. Revenue declines moderately impact financial performance, balanced by strategic initiatives.
MaxCyte, Inc. (MXCT) reported a Q4 net loss and missed revenue estimates. Q4 loss and revenue miss will moderately affect financial performance and short-term market sentiment.
23 Mar
MaxCyte, Inc. (MXCT) appoints Parmeet Ahuja as Chief Financial Officer. CFO appointment influences financial strategy, reporting, and investor sentiment.
25 Feb
MaxCyte (MXCT) launched the ExPERT DTx Platform to accelerate high-throughput drug discovery using its cell engineering technology. Launching the ExPERT DTx Platform introduces a major tool for high-throughput drug discovery, enhancing MaxCyte's competitive edge and partnership potential.
24 Feb
MaxCyte, Inc. (MXCT) launched ExPERT DTx™, a 96-well electroporation platform designed to accelerate discovery workflows in cell and gene therapy development by enabling high-throughput, scalable transfection. Unveiling ExPERT DTx™ introduces a major advancement in high-throughput electroporation, strengthening MaxCyte's core technology offerings and potential revenue from partnerships.
12 Jan
MaxCyte, Inc. (MXCT) announced its preliminary unaudited financial results for the fourth quarter and full year of 2025, highlighting significant growth in revenue and operational advancements. The company reported a substantial increase in total revenue compared to the previous year, driven by strong demand for its cell-engineering platform and expanded partnerships. MaxCyte's focus on innovation and strategic collaborations is expected to enhance its market position and drive future growth. The significant revenue growth and operational advancements indicate a major strategic move that could alter the company's trajectory.
1 Dec
Cellares has appointed Ali Soleymannezhad, the former commercial chief of MaxCyte, as its Chief Commercial Officer. Soleymannezhad will lead the global expansion of Cellares' Integrated Digital Manufacturing Operations (IDMO), drive new partnerships, and prepare the company for an initial public offering (IPO). The appointment of a former MaxCyte executive to a key role at Cellares may influence market sentiment and partnerships but does not directly impact MaxCyte's core operations.
13 Nov
MaxCyte, Inc. (MXCT) reported its Q3 2025 earnings, highlighting strategic initiatives aimed at navigating current market challenges. The company emphasized its focus on expanding its product offerings and enhancing operational efficiencies to drive growth. Despite facing competitive pressures, MaxCyte remains committed to innovation and maintaining its market position. The earnings call underscored the importance of adapting to evolving industry dynamics while pursuing long-term objectives. Strategic initiatives and product expansions are expected to significantly influence MaxCyte's future performance and market positioning.
12 Nov
MaxCyte, Inc. (MXCT) reported its financial results for the third quarter of 2025, highlighting continued growth and reaffirming its revenue guidance for the full year 2025. The company emphasized its strategic initiatives and advancements in its cell-engineering platform, which are expected to drive future revenue. Management expressed confidence in achieving the projected financial targets despite market challenges. The reaffirmation of revenue guidance and ongoing strategic initiatives indicate a moderately noticeable influence on financial performance.
5 Nov
MaxCyte, Inc. (MXCT) reported preliminary financial results for the third quarter of 2025, highlighting a continued positive trajectory in revenue. The company reiterated its full-year revenue guidance for 2025, indicating confidence in its operational performance and market position. These results reflect ongoing demand for MaxCyte's technology and services in the biopharmaceutical sector. The preliminary financial results and reaffirmed revenue guidance suggest a moderately noticeable influence on the company's financial performance and market sentiment.
6 Oct
MaxCyte, Inc. has entered into a strategic platform license agreement with Moonlight Bio to enhance T cell therapies targeting solid tumors. This collaboration aims to leverage MaxCyte's technology to advance the development of innovative cancer treatments, potentially improving patient outcomes in oncology. The partnership with Moonlight Bio represents a significant strategic move that could enhance MaxCyte's position in the oncology market.
22 Sep
MaxCyte, Inc. (MXCT) has announced an operational restructuring aimed at reducing costs and accelerating its path to profitability. The company is implementing strategic changes to streamline operations and enhance efficiency, which are expected to positively impact its financial performance moving forward. The restructuring is a significant strategic move that could alter the company's trajectory and improve investor sentiment.